Overview
Why was this study done?
This study was done to support the registration of a 3-in-1 vaccine in Russia. The 3-in-1 vaccine works
against diphtheria, tetanus, and pertussis (whooping cough).
What was studied? Who was in this study?

The researchers studied how many 447 Russian children and adults:
people built an antibody defense
111 children aged 4-9 years;
after vaccination. The antibodies
they studied were against 111 adolescents aged 10-17 years;
diphtheria, tetanus, and whooping
113 adults aged 18-64 years;
cough (pertussis).
112 older adults aged 65 and older.

Vaccine safety was also studied.
What kind of study was it? Main results
 This was an ‘open label’ study. ‘Open  One month after vaccination, at least 99%
label’ means that the study staff and of all people in the study were protected
and the people in the study knew what against diphtheria and tetanus.
vaccine was given.
 At least 97% of all people in the study had
positive antibody levels against whooping
cough (pertussis) a month after
vaccination.
NCT number: NCT03311659
EudraCT number: 2015-003405-42